Syschem India Ltd has announced the commencement of commercial production for two major manufacturing units, marking a significant milestone in the company's expansion strategy. The pharmaceutical manufacturer has successfully operationalized new production facilities that will enhance its manufacturing capabilities in key therapeutic segments.

Production Capacity Expansion

The company has achieved two major production milestones with the launch of its expanded and new manufacturing units. The details of the new production facilities are outlined below:

Manufacturing Developments

The expanded Amoxicillin unit represents a significant increase in the company's production capacity for this essential antibiotic. With a total capacity of 1200 MT, this facility commenced operations on January 5, 2026. The Amoxicillin expansion demonstrates the company's commitment to scaling up production of widely-used pharmaceutical products.

Simultaneously, Syschem India has launched a new Cloxacillin manufacturing unit with a production capacity of 600 MT. This addition diversifies the company's product portfolio and strengthens its position in the antibiotic manufacturing segment.

Strategic Impact

These production launches position Syschem India to meet increased market demand for both Amoxicillin and Cloxacillin products. The combined capacity expansion of 1800 MT across both units represents a substantial increase in the company's overall manufacturing capabilities. The timing of these launches reflects the company's strategic planning to capitalize on market opportunities in the pharmaceutical sector.

Syschem (India) Limited , a chemical manufacturing company, has announced its unaudited financial results for the second quarter and half-year ending September 30, 2025. The company's performance shows a significant shift from profit to loss compared to the previous quarter.

Financial Performance

Syschem India reported a net loss of Rs 60.54 crore for Q2 FY2026, a stark contrast to the profit of Rs 67.18 crore in the previous quarter. This decline in profitability comes alongside a decrease in revenue from operations, which fell to Rs 1,179.24 crore from Rs 1,267.58 crore in the preceding quarter.

For a clearer picture of the company's financial performance, here's a breakdown of key figures:

Half-Year Performance

For the half-year period ending September 30, 2025, Syschem India recorded a loss of Rs 422.07 crore before tax. This indicates that the company's financial challenges extend beyond the most recent quarter.

Balance Sheet Highlights

As of September 30, 2025, Syschem India's financial position shows:

• Total assets stood at Rs 2,172.62 crore
• Total equity amounted to Rs 948.60 crore
• Trade receivables decreased to Rs 697.03 crore from Rs 895.40 crore
• Inventories reduced to Rs 413.24 crore from Rs 682.78 crore

The reduction in trade receivables and inventories may suggest efforts to improve working capital management or could be a result of decreased business activity.

Board Approval and Audit Review

The Board of Directors approved these results in their meeting held on November 10, 2025. Additionally, the statutory auditors have carried out a limited review of the financial results, as stated in the company's disclosure.

Conclusion

Syschem India's Q2 FY2026 results reflect significant challenges, with a notable shift from profit to loss. The decrease in revenue and the substantial loss reported for the quarter and half-year period indicate that the company may be facing headwinds in its operating environment. Stakeholders will likely be watching closely to see how the company addresses these financial challenges in the coming quarters.